Clinical Trials
3 trialsNCT04456920 2025-12-02
BIO-PSY
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT05258747 2024-10-03
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Sandoz
Phase 1 Completed
NCT00723398 2018-11-01
Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Milton S. Hershey Medical Center
Phase NA Completed